Results 61 to 70 of about 281,748 (215)
Transfusion Medicine, EarlyView.Abstract Background Haemoglobin plays a crucial role in oxygen transport, and any acute deviation will trigger compensatory hemodynamic functions. While the consequences of anaemia are well documented, the effects of haemoglobin reduction in individuals without anaemia remain less explored. Patients with polycythaemia vera and healthy blood donors, who
Rik P. B. Tonino +3 more
wiley +1 more source
Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors
Biomedicines, 2022 This work analyses the results of research regarding the predisposition of genetic hematological risks associated with secondary polyglobulia. The subjects of the study were selected based on shared laboratory markers and basic clinical symptoms.
Nikola Slaninova +8 more
doaj +1 more source
Haematologica, 2010 Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer +2 more
doaj +1 more source
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Introduction Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort ...
Alberto Blanco‐Sánchez +8 more
wiley +1 more source
Oral Idasanutlin in Patients with Polycythemia Vera.
Blood, 2019 A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem and progenitor cells ...
J. Mascarenhas +12 more
semanticscholar +1 more source
eJHaem, Volume 6, Issue 6, December 2025.ABSTRACT Introduction Secondary and idiopathic polycythaemia is far more common than polycythaemia vera. Whilst venesection for polycythaemia vera has a robust evidence base, the data supporting this treatment for secondary and/or idiopathic polycythaemia are limited to small single‐arm studies showing transient improvement in symptoms or physiologic ...
Phillip LR Nicolson +7 more
wiley +1 more source
Trends in Research, 2019 Leukemia is a cancer of the blood and bone marrow; there are many types of leukemia, depending on which type of white blood cell is involved. Treatment varies with the type and stage of disease.
A. Heidari, R. Gobato
semanticscholar +1 more source
American Journal of Hematology, Volume 100, Issue 11, Page 2028-2039, November 2025.ABSTRACT Selecting the optimal donor is crucial for optimizing results of allogeneic hematopoietic cell transplantation (allo‐HCT). We analyzed outcomes based on donor type in 2809 myelofibrosis (MF) patients undergoing first allo‐HCT between 2015 and 2021 at EBMT centers.
Juan Carlos Hernández‐Boluda +24 more
wiley +1 more source
Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report [PDF]
, 2021 Hongfeng Wen +4 more
openalex +1 more source
Dysregulated iron metabolism in polycythemia vera: etiology and consequences
Leukemia, 2018 Polycythemia vera (PV) is a chronic myeloproliferative neoplasm. Virtually all PV patients are iron deficient at presentation and/or during the course of their disease.
Y. Ginzburg +5 more
semanticscholar +1 more source